High TDO and IDO1 Expression in Ovarian Cancer-Associated Cells

Discovery of Precision Oncology Drugs

NTRC provides in vitro drug discovery services focused on Precision Medicine. We help you to find the informed route to the clinic. More info via: www.oncolines.com

Expression of Cancer Immunotherapy Targets in Patient Material

Malignant ascites collected from epithelial ovarian cancer (EOC) patients have been used to identify biomarkers of chemotherapy response. The ascites are also used in discovery programs of small molecule inhibitors of the tryptophan (Trp) catabolizing enzymes TDO and IDO1. High surface expression of PD-L1, and high expression of IDO1 or TDO2 was observed in several patient samples. In an ongoing study, which includes 100 patients with high-grade serous ovarian cancer, NTRC determines the immune status of the ascites, the in vitro drug response of tumor cells isolated from ascites, and the cancer gene mutation. Results are related to clinical responses.

Access Cancer Cell Lines, Proliferation Assays and Bioinformatics Analysis to Find Patient Stratification Markers


Apply Combination Studies
to Identify
Novel Synergies


Use Cell-Based Assays
to Determine
Mechanism of Action


Information Needed?

Please contact us for more information